Treatment of human SS cells with our lead WDR5 PROTAC degraders, MS67 and MS40 (26–28), potently degraded cellular WDR5 in SS and efficiently inhibited malignant growth of SS cells in vitro. The gene discussed is WDR5; the disease is synovial sarcoma.